Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment and Outcomes in Myocardial Infarction and Cancer-A German Real-Life Analysis.

JACC. CardioOncology·2026

Same author

Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Annals of hematology·2026

Same author

A WHIM of the marrow: myelokathexis as a cytological clue to a rare blood disorder.

Blood·2026

Same author

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

The Lancet. Haematology·2026

Same author

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.

Scientific reports·2026

Same author

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Blood neoplasia·2026

Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Antibody-based vascular tumor targeting.

Christoph Schliemann¹, Dario Neri

¹Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zürich, Zürich, Switzerland.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer

|December 25, 2009

Summary

This summary is machine-generated.

Targeting tumor vasculature with antibodies offers a novel cancer therapy approach. This strategy selectively delivers drugs to tumors by targeting angiogenesis markers, improving cancer treatment selectivity and tolerability.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Cancer therapy increasingly focuses on inhibiting angiogenesis, the formation of new blood vessels essential for tumor growth.
Antibody-based vascular tumor targeting leverages tumors' dependence on neovasculature for selective drug delivery.

Purpose of the Study:

To review suitable angiogenesis markers for antibody-based vascular targeting.
To describe transcriptomic and proteomic methods for discovering new vascular tumor markers.
To discuss antibody-based vascular targeting strategies for cancer imaging and therapy.

Main Methods:

Selection of well-characterized angiogenesis markers.
Application of transcriptomic and proteomic methodologies for marker discovery.
Review of existing antibody-based vascular targeting strategies.

Main Results:

Several angiogenesis markers are suitable targets for antibody-based vascular targeting.
Transcriptomic and proteomic approaches can identify novel vascular tumor markers.
Antibody-based strategies are progressing in preclinical and clinical cancer studies.

Conclusions:

Antibody-based vascular tumor targeting is a promising strategy for selective cancer therapy and imaging.
Targeting tumor vasculature offers a more selective and better-tolerated approach to cancer treatment.
Continued research into novel markers and targeting strategies will advance oncological applications.